Enhancing Operational Efficiency: Time and Cost Savings of a Minimally Invasive Vascular Closure Device in Germany
Author(s)
Viktor Makowski, MBA1, Fany Kertous, Master2, Jörg Teßarek, PhD3, Aline Topouchian, PhD4.
1Market Access Manager, Terumo Deutschland GmbH, Eschborn, Germany, 2Biometrics Manager EMCD, Terumo Interventional Systems, Leuven, Belgium, 3Bonifatius Hospital Lingen, Lingen, Germany, 4Market Access and HEOR Director EMEA, Terumo Interventional Systems, Leuven, Belgium.
1Market Access Manager, Terumo Deutschland GmbH, Eschborn, Germany, 2Biometrics Manager EMCD, Terumo Interventional Systems, Leuven, Belgium, 3Bonifatius Hospital Lingen, Lingen, Germany, 4Market Access and HEOR Director EMEA, Terumo Interventional Systems, Leuven, Belgium.
OBJECTIVES: Vascular Closure Devices (VCD) are designed to achieve rapid hemostasis at the access site of percutaneous endovascular procedures (PEP). Compared to the standard of care, manual compression (MC), VCD bring meaningful time savings, earlier patient ambulation and discharge. This study evaluates the time to hemostasis (TTH) using a VCD and its associated procedural cost impact at a single reference hospital in Germany.
METHODS: Data were extracted from a prospective, multi-center observational study (ANGIOSEAL-CLOSE, NCT05335525), focusing on a subset of 73 patients treated in a German reference hospital. One secondary effectiveness endpoint of the study was the mean TTH. Cost impact was estimated by calculating the total time savings in minutes and multiplying them by the average procedural cost per minute for the hybrid operating room (OR) (with angiography unit) used at this reference hospital. The average cost was extracted from the hospital’s own DRG-cost matrix.
RESULTS: The mean TTH with VCD use was <1 minute (0.4 minutes i.e. 24 seconds) compared to 15 minutes with MC, resulting in an average time saving of 14.6 minutes per patient. Across the 73 patients, this resulted in a total time saving of 1,066 minutes (approximately 18 hours). Based on an estimated cost of €52.98 per minute (calculated from the hospital’s DRG-cost matrix and 30 min average procedure time) for a hybrid OR with angiography unit, the total cost savings amounted to € 56,462 € for the patient cohort.
CONCLUSIONS: The use of VCD led to a dramatic reduction in TTH by 97% and resulted in a 49% reduction (773,45 € per patient) in associated procedural cost for the hybrid OR. These findings support the adoption of minimally invasive VCDs to reduce the risk of complications for the patients, to enhance procedural efficiency and alleviate healthcare professionals’ workload, and enable a more resilient healthcare system.
METHODS: Data were extracted from a prospective, multi-center observational study (ANGIOSEAL-CLOSE, NCT05335525), focusing on a subset of 73 patients treated in a German reference hospital. One secondary effectiveness endpoint of the study was the mean TTH. Cost impact was estimated by calculating the total time savings in minutes and multiplying them by the average procedural cost per minute for the hybrid operating room (OR) (with angiography unit) used at this reference hospital. The average cost was extracted from the hospital’s own DRG-cost matrix.
RESULTS: The mean TTH with VCD use was <1 minute (0.4 minutes i.e. 24 seconds) compared to 15 minutes with MC, resulting in an average time saving of 14.6 minutes per patient. Across the 73 patients, this resulted in a total time saving of 1,066 minutes (approximately 18 hours). Based on an estimated cost of €52.98 per minute (calculated from the hospital’s DRG-cost matrix and 30 min average procedure time) for a hybrid OR with angiography unit, the total cost savings amounted to € 56,462 € for the patient cohort.
CONCLUSIONS: The use of VCD led to a dramatic reduction in TTH by 97% and resulted in a 49% reduction (773,45 € per patient) in associated procedural cost for the hybrid OR. These findings support the adoption of minimally invasive VCDs to reduce the risk of complications for the patients, to enhance procedural efficiency and alleviate healthcare professionals’ workload, and enable a more resilient healthcare system.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
EE411
Topic
Economic Evaluation, Medical Technologies, Real World Data & Information Systems
Topic Subcategory
Cost/Cost of Illness/Resource Use Studies
Disease
Cardiovascular Disorders (including MI, Stroke, Circulatory)